The Committee for Medicinal Products for Human Use gave a thumbs up for an eculizumab biosimilar, and a biologic license application for a bevacizumab biosimilar was accepted in Brazil.
The European Union advances an eculizumab biosimilar in its regulatory process and the Brazil Agência Nacional de Vigilância Sanitária (ANVISA) advanced a bevacizumab biosimilar.
EU Thumbs Up for Eculizumab Biosimilar
The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion on Bekemv, an eculizumab biosimilar referencing Soliris, bringing the drug one step closer to regulatory approval in the European Union.
Eculizumab is a recombinant humanized monoclonal IgG4/4k antibody that binds to the human C5 complement protein to inhibit the activation of terminal complement. It’s used to treat adults and children with paroxysmal nocturnal hemoglobinuria. Bekemv was developed by Amgen, and if approved, it would be the first biosimilar referencing Soliris to be granted marketing authorization in Europe.
Bekemv will be available as a 300-mg concentrate designed for intravenous infusion. The biosimilar would need to be administered by a health care professional and under physician supervision. Unlike the reference product, Bekemv contains sorbitol and is therefore contraindicated in patients with hereditary fructose intolerance (HFI), who may experience serious metabolic harms if exposed to sorbitol. It is also contraindicated in children younger than 2 years who have not yet received a diagnosis of HFI.
The opinion was based on data from a phase 3 study submitted in the marketing authorization application for Bekemv, which demonstrated that the biosimilar has no clinically meaningful differences from the originator.
ANVISA Accepts Bevacizumab Biosimilar Application
ANVISA accepted an application for Boan Biotech’s Boyounuo, a biosimilar referencing Genentech’s Avastin (bevacizumab). Boan Biotech is a Yantai, China–based company that develops biologics for the Chinese market as well as international markets.
Bevacizumab is a vascular endothelial growth factor inhibitor used to treat colorectal, non–small cell lung, glioblastoma, kidney, cervical, and ovarian cancers. Boyounuo launched in China in 2021 and Boan Biotech said that it is accelerating the commercial launch of the product overseas.
The Brazilian drug market was named the eighth largest pharmaceutical market in the world in 2021 by IQVIA, and it is expected to grow to be the sixth largest by 2026. Invoice spending on pharmaceutical products in Brazil is expected to reach between $47 billion and $51 billion in 2026. Currently, there are 43 ANVISA-approved biosimilars in Brazil.
In terms of the needs of local patients, data from the World Health Organization's International Agency for Research on Cancer show that, in 2020, lung cancer and colorectal cancer were among the top 5 cancers in terms of new cases in Brazil, indicating an unmet need for affordable treatments in the country.
“At Boan Biotech, we're committed to serving patients around the world with high-quality biologics. Our products are developed to address worldwide clinical needs following international quality standards. Fast-growing emerging markets including Brazil are important parts of our international business. We are accelerating the overseas development and launch of our products aiming to build a leading Chinese biopharmaceutical brand in global markets,” said Dou Changlin, PhD, president of research and development and chief operating officer of Boan Biotech, in a statement.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.